Clinical Trials Directory

Trials / Completed

CompletedNCT04431414

A Study of Immune Responses to the Virus That Causes COVID-19

A Prospective Study of Acute Immune Responses to SARSCoV-2 Infection

Status
Completed
Phase
Study type
Observational
Enrollment
953 (actual)
Sponsor
COVID-19 Prevention Network · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments.

Detailed description

This is a prospective study of acute immune responses to SARSCoV-2 infection. The study will include 3 groups, as described in the table below. Groups are defined based on clinical status at enrollment, but for the purposes of data analysis, participants who experience disease progression can contribute data to other cohorts. Participants will complete six visits over 28 days followed by a health contact at Month 2 (one month after the last scheduled visit). Additional follow up visit(s) may be added over time in response to evolving information regarding SARS-CoV-2 infection and COVID-19. Study visits may include review of medical history; interviews/questionnaires; pregnancy tests (for participants assigned female sex at birth); blood draws; nasal swab, nasal wash, and saliva sample collection; and optional stool sample collection.

Conditions

Interventions

TypeNameDescription
OTHERSample collection* blood, nasal swab, nasal wash, and saliva * optional stool swab

Timeline

Start date
2020-07-20
Primary completion
2022-06-02
Completion
2022-06-02
First posted
2020-06-16
Last updated
2022-07-26

Locations

52 sites across 11 countries: United States, Argentina, Botswana, Brazil, Malawi, Mexico, Peru, South Africa, Tanzania, Zambia, Zimbabwe

Source: ClinicalTrials.gov record NCT04431414. Inclusion in this directory is not an endorsement.